

PRESS-RELEASE

Neobiomics AB and Ewopharma AG announce an exclusive collaboration for distribution of ProPrams® in Switzerland

Schaffhausen, Switzerland, 17 May, 2021 – Neobiomics AB and Ewopharma AG have entered an exclusive distribution agreement valid for the territory of Switzerland. The agreement includes marketing and sales of Neobiomics' proprietary product ProPrams® and is in effect immediately.

Neobiomics AB is a Sweden-based company specialized in pediatric health care, connected with the Innovation Incubator at Karolinska Institutet Innovation AB. Ewopharma AG is a Swiss company focused on marketing of prescription and OTC drugs as well as Consumer Health products.

Dr. Stefan Johansson, CEO and Founder of Neobiomics AB, regards the agreement as another milestone for ProPrams®: "We at Neobiomics are very happy to work with Ewopharma. Their expertise and knowledge of the Swiss market will enable easy access to ProPrams® in Switzerland. It is great to collaborate with such an experienced team in this important territory."

Dr. Friederike Skott, Country Manager Switzerland Ewopharma AG, comments: "ProPrams®, Neobiomics' high-quality multi-strain probiotic product, represents a very good fit for our portfolio of orphan disease products. The neonatology community in Switzerland is requesting a high-grade food for special medical purposes such as ProPrams®. We are proud to respond to an unmet need for a very vulnerable group of patients with the introduction of ProPrams® and look forward to working with the passionate and knowledge-driven team at Neobiomics."

About Ewopharma AG

Ewopharma AG is a pharmaceutical marketing organization that represents pharmaceutical and biotechnology companies as their commercialization partner of choice in Central Eastern Europe and Switzerland. Ewopharma markets prescription and OTC drugs as well as Consumer Health products. Further information is available at www.ewopharma.com.

About Partner

Neobiomics AB was founded in 2016 by Stefan Johansson and Philipp Novak to solve unmet needs in pediatric health care. The first product ProPrams® is a high-quality multi-strain food supplement manufactured by Chr. Hansen, a world-wide leader in manufacturing bacterial cultures. ProPrams® is currently being used in eight European countries. Further information is available at www.neobiomics.eu.

For further information, please contact:

Neobiomics AB
Dr. Stefan Johansson
Founding Partner and CEO
info@neobiomics.eu

Ewopharma AG
Dr. Friederike Skott
Country Manager Switzerland
info@ewopharma.com